Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03786549

Pediatric -Adult Care Transition Program of Patients With Sickle Cell Disease

Background The pediatric-adult care transition is a risk-disrupting time for patients with chronic disease. This care transition takes place during adolescence; a period of psychological upheavals and adaptations of family roles. During this period, medication adherence is non-optimal and absenteeism at medical appointments is high.

Sickle cell disease (SCD) is the first genetic disease detected in France. It is chronic disease characterized by frequent painful vaso-occlusive crises (VOC) requiring emergency hospitalization when they are severe. Other serious complications are acute chest syndromes (ACS) and stroke.

In order to improve the health status of teenagers with sickle cell disease, it is necessary to anticipate this care transition and to involve the pediatric and adult sectors. The biopsychosocial health approach and the Social-Ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) describe a care transition integrating bioclinical and psychosocial factors such as integration of the patient's family, education on disease and therapeutics, psychological management of pain and medico-social orientation.

The pediatric-adult transition program proposed is based on this biopsychosocial approach. It aims to improve the health status of adolescents with SCD, their quality of life and the use of health care service.

Objective of the study To assess the impact of a pediatric-adult transition program on the incidence of sickle-cell-related complications leading to hospitalization on 24-months after transfer to the adult sector.

The evaluation focuses on severe complications leading to hospitalization, such as VOC, ACS, and stroke.

Study design Multicenter Open-label individual Randomized Controlled Trial Population : Patients aged at least 16 years old with sickle cell disease, and their parents (or legal representatives Number of subject : 196 patients (98 patients by arm) The study will last 24 months Expected results For patients and families Better health and quality of life for patients is expected, including better use of medical care after the transition program. It is also expected a better experience of the pediatric-adult care transition and indirectly a better experience of intrafamilial relations.

For health professionals This project is expected to provide solutions to improve the pediatric-adult care transition of patients with chronic disease. Indeed, the methodological quality of the study will make it possible to evaluate the efficiency of the proposed program, to possibly adapt it and test it to other chronic diseases presenting the same care transition problematic.

In terms of public health SCD mainly affects populations of sub-Saharan origin, with low visibility and high social vulnerability. By focusing on this population, this project will reduce the social inequalities in health, experienced by patients with SCD and their families.

By improving the health, quality of life and care of patients with SCD, this project is expected to decrease the cost of the pediatric-adult care transition period.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Fort de France, Fort-de-France-La Martinique, La Martinique, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For patients :

  • Age: 16-17 years,
  • With major sickle cell syndrome, defined by hemoglobinopathy of homozygosity SS, or double heterozygosity SC or Sβ-thalassemia,
  • Benefiting from social insurance of the type "Affection of long duration" (ALD).

For family members :

  • Included children's parents or legal representatives,
  • Accepting to participate in the study and having signed the informed consent.

Exclusion criteria

  • Presenting a cognitive or psychiatric disorder known and major that may hinder interventions or evaluation, the judgment of the investigator, and / or having a family history with this type of disorders,
  • Cured of SCD by an allograft of hematopoietic stem cells.

Treatment and study plan

pediatric-adult care transition program

Other

Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent

Three axes are :

  • Educative, family (patient and parent), at home
  • Psychological, with the patient individually
  • Medico-social orientation, group of patients

Primary outcomes

  1. Incidence of sickle cell related severe complications leading to hospitalization

    Time frame: Within 24 months after transfer to the adult sector

    Number of hospital admission or emergency visit in the index hospital

Secondary outcomes

  1. Frequency of emergency visits in the index hospital

    Time frame: Up to 2 years

    Frequency of emergency visits in the index hospital Within inclusion and transfer to the adult sector

  2. Frequency of emergency visits in the index hospital

    Time frame: Within 12 months after transfer to the adult sector

  3. Frequency of emergency visits in the index hospital

    Time frame: Within 12 and 24 months after transfer to the adult sector

  4. Medication Intake Survey-Asthma (MIS-A) questionnaire score

    Time frame: At inclusion

    Medication adherence evaluation at inclusion

  5. Medication Rating Scale (MARS) questionnaire score

    Time frame: At inclusion

    Medication adherence evaluation at inclusion

  6. MIS-A questionnaire score

    Time frame: Up to 2 years

    Medication adherence evaluation At transfer to the adult sector

  7. MARS questionnaire score

    Time frame: Up to 2 years

    Medication adherence evaluation At transfer to the adult sector

  8. MIS-A questionnaire score

    Time frame: within 12 months after transfer to the adult sector

    Medication adherence evaluation within 12 months after transfer to the adult sector

  9. MARS questionnaire score

    Time frame: within 12 months after transfer to the adult sector

    This score will allow medication adherence evaluation within 12 months after transfer to the adult sector

  10. MIS-A questionnaire score

    Time frame: within 24 months after transfer to the adult sector

    Medication adherence evaluation within 24 months after transfer to the adult sector

  11. MARS questionnaire score

    Time frame: within 24 months after transfer to the adult sector

    Medication adherence evaluation within 24 months after transfer to the adult sector

  12. Number of days absent at school

    Time frame: Up to 2 years

    Scholarly Absenteeism evaluation At transfer to the adult sector

  13. Number of days absent at school

    Time frame: within 12 months after transfer to the adult sector

    Scholarly Absenteeism evaluation within 12 months after transfer to the adult sector

  14. Number of days absent at school

    Time frame: within 24 months after transfer to the adult sector

    Scholarly Absenteeism evaluation within 24 months after transfer to the adult sector

  15. World Health Organization Quality of Life (WHOQOL) questionnaire score

    Time frame: At inclusion

    Quality of Life evaluation At inclusion

  16. WHOQOL questionnaire score

    Time frame: Up to 2 years

    Quality of Life evaluation At transfer to the adult sector

  17. WHOQOL questionnaire score

    Time frame: within 24 months after transfer to the adult sector

    Quality of Life evaluation within 24 months after transfer to the adult sector

  18. EUropean Health Literacy questionnaire (HLS-EU-Q16) score

    Time frame: At inclusion

    This will allow Health Literacy evaluation

  19. HLS-EU-Q16 score

    Time frame: Up to 2 years

    Health Literacy evaluation At transfer to the adult sector

  20. HLS-EU-Q16 score

    Time frame: within 24 months after transfer to the adult sector

    Health Literacy evaluation within 24 months after transfer to the adult sector

  21. Disease knowledge

    Time frame: At inclusion

    Questionnaire developed for this study

  22. Disease knowledge

    Time frame: Up to 2 years

    Questionnaire developed for this study

  23. Disease knowledge

    Time frame: within 24 months after transfer to the adult sector

    Questionnaire developed for this study

  24. Patient activation measure-13 items questionnaire score

    Time frame: At inclusion

    Patient activation At inclusion

  25. Patient activation measure-13 items questionnaire score

    Time frame: Up to 2 years

    Patient activation At transfer to the adult sector

  26. Patient activation measure-13 items questionnaire score

    Time frame: within 24 months after transfer to the adult sector

    Patient activation within 24 months after transfer to the adult sector

  27. Self efficacy specific instrument - sickle cell disease (SCD-SES) questionnaire score

    Time frame: At inclusion

    Self efficacy evaluation at inclusion

  28. SCD-SES questionnaire score

    Time frame: Up to 2 years

    Self efficacy evaluation At transfer to the adult sector

  29. SCD-SES questionnaire score

    Time frame: within 24 months after transfer to the adult sector

    Self efficacy evaluation within 24 months after transfer to the adult sector

  30. Transition readiness assessment questionnaire (TRAQ) questionnaire score

    Time frame: At inclusion

    Transition readiness evaluation at inclusion

  31. TRAQ questionnaire score

    Time frame: Up to 2 years

    Transition readiness evaluation At transfer to the adult sector

  32. TRAQ questionnaire score

    Time frame: within 24 months after transfer to the adult sector

    Transition readiness evaluation within 24 months after transfer to the adult sector

  33. cost effectiveness ratio

    Time frame: Up to 4 years

    Cost analysis at the end of the study

  34. number of pediatric-adult transition program sessions performed

    Time frame: Up to 4 years

    number of interventions performed per patient and date of implementation At the end of the study

  35. type of pediatric-adult transition program sessions performed

    Time frame: Up to 4 years

    type of interventions performed per patient and date of implementation At the end of the study

Study contacts

Contact information is provided by the study sponsor or research team.

Alexandra GAUTHIER VASSEROT, DR

CONTACT

[email protected]

04 69 16 65 72 ext. +33

Sandrine TOUZET, Dr

CONTACT

[email protected]

04 72 11 57 61 ext. +33

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Impact of a Pediatric-adult Care Transition Program on the Health Status of Patients With Sickle Cell Disease - A Randomized Controlled Trial

Acronym: DREPADO

Important dates

Study start
2019
Primary completion
2027
Study completion
2027
First posted
Dec 26, 2018
Registry last updated
Jun 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.